Zanubrutinib remains unfunded in New Zealand
Zanubrutinib has been publicly funded and accessible for the treatment Chronic Lymphocytic Leukaemia (CLL) in Australia for more than two years, offering patients a targeted therapy option with proven efficacy and tolerability.
Its availability across the Tasman highlights the growing disparity in access to innovative blood cancer treatments between Australia and New Zealand.
In light of the Government’s failure to deliver on its pre-election commitment to fund blood cancer medicines, this is a clear priority for advocacy ahead of next year’s general election.
Read more here: https://healthtree.org/cll/community/articles/zanubrutinib-leads-in-covalent-btk-inhibitors?